Efficacy and safety of current therapies for difficult-to-treat rheumatoid arthritis: a systematic review and network meta-analysis
Journal of Translational Medicine 2024;22:795
Su et al. conducted a comprehensive systematic review and network meta-analysis to assess the efficacy and safety of therapies for difficult-to-treat (D2T) RA. They found that tocilizumab and rituximab had superior efficacy and safety profiles, with 8mg every 4 weeks of tocilizumab identified as the optimal therapeutic dose.
The study utilised Bayesian network meta-analysis to examine results from 42 RCTs, including therapies targeting various mechanisms such as IL-6 and JAK inhibition. The study aimed to offer a comprehensive evaluation of treatments for D2T RA to support clinical decision-making.
Keywords:
